منابع مشابه
HLA-identical sibling stem-cell transplantation in first-remission AML.
transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513-521. 6. Druker BJ, Guilhot F, O' Brien S, et al. Five-year follow-up of patients receiving ima-tinib for chronic myeloid leukemia. In t...
متن کاملOptimal induction and post-remission therapy for AML in first remission.
Approximately 300,000 patients in the world are diagnosed annually with acute myeloid leukemia (AML). The median age at presentation has been steadily increasing over the past few decades and now is approaching 70 years. Although considerable progress has been made over the past 3 decades in the therapy of AML, two thirds of young adults still die of their disease. The therapy of AML, unlike ac...
متن کاملSpontaneous Remission in Congenital Leukemia AML-M1 with Pericardial Effusion
Congenital leukemia is a very rare malignancy of childhood with a poor prognosis. The incidence is nearly 1 in 5 million live births. The majority of cases are acute myeloblastic leukemia with trisomy. Clinical manifestations are usually leukocytosis, petechia, ecchymosis, cutaneous nodules, hepatosplenomegaly and central nervous system symptoms. 23-days old girl was presented with complaints o...
متن کاملSpontaneous remission in three cases of AML M5 with NPM1 mutation
Patients with NPM1-mutated AML M5 who develop spontaneous remission (SR) after antibiotic therapy at diagnosis seem to form a favorable prognosis and chemo sensitive subtype. We report three cases of AML M5 patients with the same genotype that experienced transient SR and are now leukemia free after standard treatment.
متن کاملA phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
IPH2101 is an anti-killer inhibitory receptor (anti-KIR) mAb that can block KIR-mediated inhibition of natural killer (NK) cells to enhance cytotoxicity against acute myeloid leukemia blasts. We have conducted a phase 1 study of IPH2101 in elderly patients with acute myeloid leukemia in first complete remission. Patients received escalating doses (0.0003-3 mg/kg) of IPH2101 following a 3 + 3 de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Info Onkologie
سال: 2012
ISSN: 1613-3633
DOI: 10.1007/s15004-012-0421-y